September 2016, Vol. 5, No. 7
Treating Nausea as a Symptom Cluster
Nausea is part of a symptom cluster associated with chemotherapy, but the experience of nausea might be a symptom cluster in and of itself, according to research presented by Ian Olver, MD, at the 2016 Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) Annual Meeting on Supportive Care in Cancer.1
When treating chemotherapy-induced nausea and vomiting, he said patients often describe nausea as a variety of symptoms. “So if you don’t treat nausea as a symptom cluster, the patient won’t tell you the nausea has gone away,” said Dr Olver, President of MASCC and Director of the Sansom Institute for Health Research, as well as Professor of Translational Cancer Research and Dean of Research Strategy in the Division of Health Sciences at the University of South Australia. “This might explain why antiemetics are only having a limited effect.”
Alex Molassiotis, RN, PhD, Professor and Head of the School of Nursing at the Hong Kong Polytechnic University, agreed, stating that “nausea may be broader than we think. We often connect it with vomiting, but perhaps there are other issues to consider.”
Triple antiemetic therapy has been successful in controlling vomiting in up to 90% of patients, Dr Olver reported. But studies suggest as many as 75% of patients undergoing chemotherapy will report nausea at some stage, whereas others endure anticipatory or conditioned nausea years after active treatment.
Patient Perception of Nausea
Through the use of semistructured interviews, Dr Olver and colleagues conducted a study on 2 groups of cancer patients with current (n = 21) or past (n = 21) experience of chemotherapy-induced nausea (CIN) to evaluate patients’ perceptions of nausea.2
According to Dr Olver, the nature, number, location, duration, and intensity of experiences described as nausea varied across both groups. No single symptom was common to all descriptions, reinforcing the investigators’ hypothesis that nausea was indeed a symptom cluster.
Physical and psychological symptoms described by the patients in the study included dry heaving, vomiting, loss of appetite, indigestion, change of taste, dizziness, bloating, reflux, inability to concentrate, fatigue, and physical restlessness. “All of these symptoms were part of what the patients recognized as nausea and therefore part of what we have to treat in order to completely alleviate it,” he said. Patients’ recognition of the site of their nausea also varied, from the upper and lower stomach to the head and throat, while some described it as a whole body experience.
The onset of nausea ranged from immediate to day 5 postchemotherapy, and duration ranged from 1.5 hours to 6 months, whereas conditioned stimuli (eg, the smell of the disinfectant used in their treatment center) could trigger nausea in survivors for years after treatment.
“If we’re looking at parameters of measuring nausea, duration is very important,” said Dr Olver. “If a patient has 6 hours of nausea, even if it’s mild, that’s perhaps far more serious than intense nausea for half an hour. So we’ve got to have a tool to measure both the intensity and the duration of nausea.”
Physical and Psychological Distress
For most patients in the study, distinguishing features of CIN (as opposed to other types of nausea, such as motion sickness) included its constant presence over time, a feeling of fatigue, and its negative impact on social and work interactions. “They were scared of feeling nauseated, so they didn’t want to wander too far from their desk or from the bathroom,” Dr Olver noted. “It restricted what they could do.” Patients also cited its significant effect on their eating patterns and appetite and said that antiemetics reduced the intensity of their nausea, but did not completely alleviate it.
Nonpharmacologic management techniques such as distraction and relaxation were found to be helpful among the study population. “When they were working, watching TV, or relaxing, they didn’t report as much nausea,” he added.
Many patients felt distressed because their nausea became a constant reminder of their cancer diagnosis. However, this was sometimes reassuring to patients because they associated the feeling of nausea with the knowledge of being treated for their cancer. Changes in social behavior, particularly when they were denied the social interaction of eating with friends and family, also took a toll on patients, he observed.
Improving Patient Quality of Life
Dr Olver emphasized the importance of treating each of the component symptoms of nausea with either drugs (olanzapine, cannabinoids, antacids, etc) or nonpharmacologic methods (diet, distractions, etc), and noted that more studies evaluating the use of cannabinoids for nausea will emerge over the next few years.
“In the future it may be possible to discover what these symptom clusters are and treat them,” he said. “We want to try to develop an electronic patient-reported outcome tool to identify and assess components of the larger nausea symptom cluster over the course of chemotherapy.”
According to Dr Molassiotis, “We haven’t focused enough on the major problem of nausea, and we need to start thinking about managing the entire cluster of symptoms, otherwise we’re not going to see good results in the near future.”
“I think that nausea is the new battleground,” added Dr Olver. “Maybe we have to treat the anxiety or indigestion or whatever other symptom patients are calling nausea in order to drive the nausea scores to zero. And if we develop a more holistic approach to nausea than we have to vomiting, we may be more successful in that sense.”
- Olver I. Nausea as a symptom cluster. Presented at: MASCC/ISOO Annual Meeting on Supportive Care in Cancer; June 23-25, 2016; Adelaide, Australia. Abstract PS051.
- Olver IN, Eliott JA, Koczwara B. A qualitative study investigating chemotherapy-induced nausea as a symptom cluster. Support Care Cancer. 2014;22:2749-2756.
Exploring Topics in Personalized Medicine to Improve the Patient Experience, Quality of Life, and Therapeutic Outcomes
Dear Colleague, The vast majority of our coverage in Personalized Medicine in Oncology focuses on our ability to identify genetic mutations, unique protein expressions, and other significant biomarkers for which we can tailor individual therapy. In this issue, we broaden that scope by exploring several topics that are related to [ Read More ]
Because of the recent approval by the FDA of the DigniCap system1 and growing evidence that scalp cooling is an effective treatment for preventing chemotherapy-induced alopecia, the practice is steadily becoming more widespread in the United States. And Hope S. Rugo, MD, is leading the charge on educating patients and [ Read More ]